🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,589 results for “Pharma” Clear

  1. INZ-701, INZ-701

    Lacuna Pharma Pty Ltd

    Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

    phase 3 small molecule active

    1 trial

  2. ION 682884, ION 682884

    IONIS PHARMACEUTICALS INC

    Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

    phase 3 small molecule active

    1 trial

  3. ION 682884, Placebo injection, 0.8 ml (is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in Water for Injection) for subcutaneous administration

    IONIS PHARMACEUTICALS INC

    Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

    phase 3 small molecule active

    1 trial

  4. ION363

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    1 trial

  5. ION363, ION363, Artificial Cerebrospinal Fluid (aCSF) for Injection, 5.0 mL (Placebo)

    IONIS PHARMACEUTICALS INC

    Amyotrophic Lateral Sclerosis with Fused in Sarcoma mutations

    phase 3 small molecule active

    1 trial

  6. ION582

    IONIS PHARMACEUTICALS INC

    Angelman Syndrome

    phase 3 small molecule active

    2 trials

  7. ION582

    IONIS PHARMACEUTICALS INC

    Angelman syndrome

    phase 3 small molecule active

    1 trial

  8. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical hemolytic uremic syndrome

    phase 3 small molecule active

    1 trial

  9. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  10. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  11. IPTACOPAN HYDROCHLORIDE

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  12. IPTACOPAN, LNP023

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  13. IRINOTECAN

    COLLEGIUM PHARMACEUTICAL, INC

    Gastric Carcinoma

    phase 3 small molecule active

    1 trial

  14. IRINOTECAN , FLUOROURACIL , OXALIPLATIN , CALCIUM LEVOFOLINATE , CALCIUM FOLINATE

    Pari Pharma GmbH

    Middle or low locally advanced resectable rectal carcinoma

    phase 3 small molecule active

    1 trial

  15. ISIS 3521

    IONIS PHARMACEUTICALS INC

    Lung Cancer

    phase 3 mab completed

    1 trial

  16. ISIS 678354

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome

    phase 3 small molecule active

    1 trial

  17. ISIS 678354, ISIS 678354, ISIS 678354

    IONIS PHARMACEUTICALS INC

    Familial Chylomicronemia Syndrome (FCS)

    phase 3 small molecule active

    1 trial

  18. ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema

    phase 3 small molecule active

    1 trial

  19. ISIS 721744, ISIS 721744

    IONIS PHARMACEUTICALS INC

    Hereditary Angioedema (HAE)

    phase 3 small molecule active

    1 trial

  20. IVA

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials

  21. IVEMEND 150 mg powder for solution for infusion, fosnetupitant chloride 260 mg/palonosetron 1.5 mg, fosnetupitant chloride 260 mg/palonosetron 2.5 mg, Ondansetrone Hikma 8 mg/4 ml Soluzione iniettabile, Sodium Chloride Injection BP 0.9% w/v

    Helsinn Birex Pharmaceuticals Ltd

    Chemotherapy-induced nausea and vomiting

    phase 3 small molecule active

    1 trial

  22. IW-3718

    IRONWOOD PHARMACEUTICALS INC

    Gastroesophageal Reflux Disease (GERD)

    phase 3 small molecule terminated

    2 trials

  23. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia (ITP)

    phase 3 mab active

    1 trial

  24. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia

    phase 3 mab active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources